Updated Summary: Pain: assessment, non-opioid treatment approaches and opioid management. [Institute for Clinical Systems Improvement]


Original post, click here

Note from the National Guideline Clearinghouse (NGC) and the Institute for Clinical Systems Improvement (ICSI): The recommendations for pain assessment, non-opioid treatment approaches and opioid management are presented in the form of a table with a list of evidence-based recommendations and 4 algorithms, accompanied by detailed annotations. The algorithm is provided in the original guideline document at the ICSI Web site for Pain: Assessment, Non-Opioid Treatment Approaches and Opioid Management (see the “Guideline Availability” field) .

Assess Quality-of-Life, Function and Pain

Work Group Recommendation: Use validated tools to assess and document the patient’s functional status, quality-of-life and pain intensity.

  • Benefit: Standardized assessment tools offer consistency for the documentation of pain intensity and physical function.
  • Harm: Clinicians may rely too much on tools, which are only one component of the clinical evaluation.
  • Benefit-Harms Assessment: Validated tools provide accurate information for the creation and the ultimate success of progress with a treatment plan. If no tools are utilized, the assessment of the patient becomes subjective.
  • Relevant Resources: Keller et al., 2004

Determine the Pain Generator

Opioid-Related Alterations in Pain Processing and Acute Opioid Withdrawal

Work Group Recommendation: Patients presenting with an indeterminate pain generator should be assessed for exposure to opioids in the past and current opioid use. Providers should consider checking the prescription monitoring program for patients presenting with pain if his or her past opioid exposure is uncertain.

  • Benefit: Patients with past exposure to opioids have a different set of expectation and risks, and may suffer from a different set of pain generators than those who are opioid naïve. Patients with past exposure to opioids may have known drug interactions or adverse effects that would affect management decisions.
  • Harm: It will take additional time to discuss opioid status during the patient encounter.
  • Benefit-Harms Assessment: As the proportion of Americans being exposed to opioids grows, the assessment of opioid exposure becomes increasingly important in patients presenting with pain. Knowing if the patient has been exposed to opioids at the time of his or her pain presentation provides both diagnostic and management information. The prevalence of opioid use is great enough to now justify the burden of assessing opioid use routinely in patients who present with an indeterminate pain generator.
  • Relevant Resources: Nuckols et.al., 2014; Cicero et al., 2014; Chu, Clark, & Angst, 2006

Dental/Orofacial Pain Diagnosis and Treatment

Treatment

Work Group Recommendation: Prescribe ibuprofen and acetaminophen combination as first-line treatment for dental pain. The referring medical clinician for acute dental pain should not routinely prescribe opioid medications.

  • Benefit: Public and patient safety. The combination of ibuprofen and acetaminophen is more effective and has fewer side effects than opioids.
  • Harm: None known because it gives the clinician an effective non-opioid option for pain relief.
  • Benefit-Harms Assessment: Compassionate, non-opioid oral/facial pain relief before and after the treatment of the underlying cause of the pain can almost always be accomplished and avoids the serious risk that accompanies every dose of an opioid mediation prescribed.
  • Relevant Resources: Moore & Hersh, 2013

Assess Physical and Behavioral Health Comorbidities

Behavioral Health Assessment

Work Group Recommendation: Assess for behavioral health comorbidities in patients with chronic pain.

  • Benefit: Could reveal key barriers in patient’s underlying suffering and improve treatment outcome.
  • Harm: Could re-expose patient to sense of being traumatized and thereby contribute to flashbacks, nightmares, emotional numbing or outburst.
  • Benefit-Harms Assessment: Correct identification of potential underlying behavioral conditions allows for more efficient treatment and the resolution of important contributing factors that could otherwise complicate chronic pain conditions.
  • Relevant Resources: Hooten, 2016; Janssens et al., 2015; Asmundson & Katz, 2009

Substance Abuse, Dependence, and Addiction

Work Group Recommendation: Consider screening patients for substance use disorders when there is an unclear etiology of pain.

  • Benefit: Many sources of pain are caused directly or indirectly by the use of addictive substances. Pain treatment decisions are greatly affected by the presence of a substance use disorder (SUD). Screening, brief intervention and referral to treatment (SBIRT) is a routine recommendation for doctors in primary care and emergency care settings, and a pain presentation should trigger an SBIRT.
  • Harm: Patients may feel that they are treated with suspicion. Performing a substance use disorder screening for patients in pain will consume provider time.
  • Benefit-Harms Assessment: Substance use disorder informs the diagnosis and complicates the treatment of pain in many patients and many settings. There will be numerous patients screening negative for whom the screening was not necessary. But for those who screen positive, the benefit is more appropriate care.
  • Relevant Resources: Han et al., 2015; Hooten et al., 2015; Jones, 2013; Juurlink & Dhalla, 2012; Sehgal, Manchikanti, & Smith, 2012; Bohnert et al., 2011; Liebschutz et al., 2010; Chou et al., “Opioids,” 2009; Martell et al., 2007

Develop Pain Treatment Plan

Work Group Recommendation: When feasible, a multidisciplinary approach is recommended for treating the patient with pain, especially chronic pain.

  • Benefit: The complexities of chronic pain require a complex biopsychosocial approach using a multidisciplinary care team.
  • Harm: Not all clinicians have access to psychologists, addiction treatment, physical therapy, or interventional specialists.
  • Benefit-Harms Assessment: The chronic pain patient will benefit from multidisciplinary care, even if it is done in a virtual setting and managed by the primary clinician.
  • Relevant Resources: International Association for the Study of Pain, 2014; Gatchel & Okifuji, 2006

Psychotherapy Strategies

Work Group Recommendation: Psychotherapy, such as cognitive behavioral therapy or mindfulness-based stress reduction, is recommended for patients with a chronic pain diagnosis.

  • Benefit: Builds patient adherence to a treatment plan. Helps patients replace maladaptive cognitions and behaviors with more adaptive ones.
  • Harm: Minimal (if any) adverse side effects of psychotherapy.
  • Benefit-Harms Assessment: This could help bring a more complete sense of healing for the patient. Studies show decreased pain, more active and better quality of life, and better general health. Lack of clinicians with expertise or training could pose an access problem.
  • Relevant Resources: International Association for the Study of Pain, 2014; Kamper et al., 2014; Castro et al., 2012; Grossman et al., 2007; Gillis et al., 2006; Turner, Mancl, & Aaron, 2006; Broderick, Junghaenel, & Schwartz, 2005; Smyth & Helm, 2003

Physical Rehabilitation Modalities

Work Group Recommendation: Exercise should be a component of the treatment for a patient with chronic pain.

  • Benefit: Exercise improves chronic pain symptoms and functional status, and bolsters overall health and sense of well-being.
  • Harm: There may be potential exacerbation of underlying, or undiagnosed, musculoskeletal injury, cardiovascular or neurologic disease.
  • Benefit-Harms Assessment: There is not one particular exercise that is superior, and the optimal frequency has not been demonstrated. The current evidence suggests at least 2 to 3 exercise sessions per week are necessary for clinical benefit.
  • Relevant Resources: Falla et al., 2013; Cuesta-Vargas et al., 2011; Standaert et al., 2011; Dufour et al., 2010; Hall et al., 2008; Hurwitz et al., 2008; Hayden et al., 2005

Work Group Recommendation: Passive modalities should be performed only as an adjunct to a concomitant active physical therapy or exercise program.

  • Benefit: Passive physical treatments provide short-term pain relief and potential medium-term benefit.
  • Harm: There is minimal risk of harm when applied by trained practitioners.
  • Benefit-Harms Assessment: Recommend passive treatments only as a complement to an active therapy or exercise program.
  • Relevant Resources: Vincent et al., 2013; Standaert et al., 2011

Work Group Recommendation: Extending physical therapy beyond 8 to 12 weeks for chronic pain patients should be based on objective clinical improvement.

  • Benefit: Physical therapy facilitates rehabilitation and optimizes functional performance in chronic pain patients when used appropriately.
  • Harm: There may be additional resources and cost for patients and service providers without evidence of improved outcomes.
  • Benefit-Harms Assessment: An active physical therapy program is recommended. Deconditioned pain patients should begin with a graded or progressive physical therapy program to minimize risk of exercise associated injury, and improve patient engagement and compliance.
  • Relevant Resources: Cuesta-Vargas et al., 2015; Cramer et al., 2013; Falla, 2013; Standaert et al., 2011; Dundar et al., 2009; Koumantakis, Watson, & Oldham, 2005; Rainville et al., 2002

Pharmacologic Treatment

Non-Opioid Medications

Work Group Recommendation: Sedative hypnotics including benzodiazepines and carisoprodol should be rarely used and if so for short-term (<1 week) treatment of muscle spasms related to acute pain. Use of non-sedative hypnotic muscle relaxants are of low benefit, but if used, limit to less than four weeks. Do not use carisoprodol for pain.

  • Benefit: Skeletal muscle relaxants are better than placebo but not more effective than nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of low back pain. Sedative hypnotics are effective for treating anxiety and muscle spasms in acute pain.
  • Harm: Muscle relaxants are central nervous system (CNS) depressants and cause additive sedation and other adverse effects, especially in combination with opioids. Sedative hypnotics have significant side effects, specifically in the geriatric population. Additive side effects when taken with other CNS depressants are potential for dependence and withdrawal symptoms.
  • Benefit-Harms Assessment: Muscle relaxants should not be used as the standard first-line treatment but may provide short-term benefit in some patients. Risk of significant side effects and potential for dependence and withdrawal outweigh the benefit for long-term use.
  • Relevant Resources: American Geriatrics Society 2015 Beers Criteria Update Expert Panel, 2015; Gray et al., 2015; Petrov et al., 2014; Richards et al., 2012; Liu et al., 2010; Chou et al., 2007; van Tulder et al., 2003

Opioid Management

Risk Assessment

Before initiating opioids for pain, providers should seek a specific diagnostic cause of the pain, and document objective findings on physical exam or other objective tests.

Risk Assessment Tools

Work Group Recommendation: Opioid risk assessment tools and knowledge of opioid-related risks should be used in combination with the overall clinical picture to guide care, including the decision to prescribe as well as how closely to monitor.

  • Benefit: Assessment of opioid-related risks may help physicians weigh risks against benefits when deciding if to prescribe opioids. In addition, knowledge of the risk factors for the various adverse outcomes of opioids helps physicians determine the intensity of monitoring and follow-up for patients. Reviewing the risks also serves as a patient education tool.
  • Harm: The use of risk assessment tools does not have an adequate sensitivity or specificity to predict opioid-related harms or to rule them out. Universal precautions should be used for all patients receiving opioids. Using risk assessment tools has not been shown to improve clinical outcomes. Risk assessment tools should not be used to exclude patients with mental health or addictive disorders from proper treatment of pain.
  • Benefit-Harms Assessment: Used correctly, knowledge of the risks of opioid related harm, including risk assessment tools, can help providers more carefully monitor those at high risk. In cases where the risk/benefit of opioids is uncertain, risk assessment can tip the provider against use of opioids. These tools can also be used incorrectly; for instance, they cannot be used to assure a patient that he or she has no risk, and they should not be used to exclude mentally ill patients from routine treatment of pain.
  • Relevant Resources: Volkow & McLellan, 2016; Wasan et al., 2015; Argoff, Kahan, & Sellers, 2014; Jones et al., 2014; Atluri, Akbik, & Sudarshan, 2012; Jones et al., 2012; Moore et al., 2009

Special Populations

Pregnant, Lactating or Women of Childbearing Age

Work Group Recommendation: Prior to prescribing opioids, women of childbearing age should be counseled on the risks of opioids in pregnancy and on contraception, and offered pregnancy testing.

  • Benefit: There may be teratogenic effects to opioids. Neonatal abstinence syndrome is costly and burdensome on the family and medical system. Opioid withdrawal in pregnancy may compromise obstetrical outcomes. Many opioid prescribers are uncomfortable continuing opioids in pregnancy.
  • Harm: There is no harm in counseling the patient. Counseling takes additional time during the patient encounter.
  • Benefit-Harms Assessment: The use of opioids in women of childbearing age, and in pregnancy, is widespread. Most pregnancies are unaffected by exposure to low dose or intermittent opioids. Some pregnancies are affected, including a low rate of teratogenicity, rising neonatal abstinence syndrome rates, and challenging the comfort of the opioid prescriber and the obstetrician. A discussion on the risks and benefits of opioids use seems prudent for this population.
  • Relevant Resources: Desai et al., 2015; Han et al., 2015; Desai et al., 2014; Maeda et al., 2014; Whiteman et al., 2014; Yazdy et al., 2013; Broussard et al., 2011

Geriatrics

Work Group Recommendation: Geriatric patients should be assessed for risk of falls, cognitive decline, respiratory malfunction, and renal malfunction before receiving opioids. If impairment or risk is detected in a geriatric patient, initiation of opioids should be at half the usual dose.

  • Benefit: Doing a unique assessment for geriatric patients is important because of this group’s unique vulnerabilities. Lowering the dose of opioids may lower the risk of opioid-related harm, such as falls and respiratory suppression, in this population.
  • Harm: Geriatric patients are a diverse group of patients, some more fragile and others more robust. They should not be treated as having equal risk of opioids as a group. The most fragile geriatric patients may also have contraindications to the common alternatives to opioids. This may lead to undertreatment of pain.
  • Benefit-Harms Assessment: Like many of the high-risk populations, using special precautions and lower doses in the geriatric population lowers the risk of opioid-related harms while also risking undertreating pain.
  • Relevant Resources: Han et al., 2015; Makris et al., 2014; Rubin, 2014; Rolita et al., 2013; Saunders et al., 2010; Solomon et al., 2010; Spector et al., 2007; Vestergaard, Rejnmark, & Mosekilde, 2006

Prescriber Responsibility with Opioid Prescription

Patient Education and Shared Decision-Making

Work Group Recommendation: The first opioid prescription should include patient education, shared decision-making and assessment for related risks.

  • Benefit: Appropriate informed consent and shared decision-making should occur early in the course of prescribing opioids. Much opioid-related harm, including overdose, can happen early in the course of pain treatment. Aberrant behaviors and comorbidities should be identified as early as possible. Patient expectations should be set early in the course of opioid treatment.
  • Harm: Patients may feel that they are being treated with suspicion. Very low-risk patients will be asked to spend time and energy to receive opioids. Clinician time and clinical resources will be dedicated early in the course of opioid prescribing.
  • Benefit-Harms Assessment: Early patient education, re-education, screening for comorbidities and detecting aberrant behaviors represent a burden to patients and clinicians that is outweighed by the benefit of promptly addressing opioid-related harms and providing the patient with up-to-date and thorough education about the risks of opioids. This approach emphasizes universal precautions.
  • Relevant Resources: Hooten, Lamer, & Twyner, 2015

Safe Use, Storage and Disposal

Work Group Recommendation: Patients newly on opioids, or having recently had their opioid dose increased, should be advised not to operate heavy machinery, including driving a car, or participate in other work or home activity that may be affected by the sedating effect of opioids. An individualized approach that weighs the risks and benefits of driving and other activities should be taken with patients chronically on stable opioids who have tolerance and do not show evidence of sedation.

  • Benefit: The sedating effect of opioids impairs one’s ability to drive a motor vehicle and carry out other tasks similarly sensitive to wakefulness and reaction time. As a safety measure, it is important to clearly warn patients about the risk to themselves and others performing potentially dangerous tasks while on opioids. With the development of opioid tolerance and the absence of sedation, studies have shown that patients can safely drive a motor vehicle.
  • Harm: Driving, work and household prohibitions can be burdensome and may prevent timely return to normal life activities.
  • Benefit-Harms Assessment: The risk to public safety of patients newly on opioids operating motor vehicles and carrying out similar tasks clearly outweighs the inconvenience to the individual on opioids. Determining when the patient has enough tolerance to safely drive is a subjective judgment call, and prescribers should err on the side of caution and document carefully.
  • Relevant Resources: National Highway Traffic Safety Administration, 2016; Schisler, Groninger, & Rosielle, 2012

Work Group Recommendation: Clinicians should discuss storage and opioid disposal options with patients at the first opioid prescription and in follow-up visits as needed.

  • Benefit: Proper storage and disposal can reduce opioids involved in diversion and overdose.
  • Harm: There are no easy options for disposal of opioids.
  • Benefit-Harms Assessment: Considering the great harm of excess opioids to the community, every opioid prescription should be accompanied with storage and disposal information. Disposal information is everchanging and complicated. While communicating the information is not highly burdensome, staying abreast of the latest information may be.
  • Relevant Resources: Dowell, Haegerich, & Chou, 2016; Centers for Disease Control and Prevention, 2010

Opioid Formulation

Work Group Recommendation: Long-acting opioids should be reserved for patients with established opioid tolerance and in whom the prescriber is confident of medication adherence. Long-acting tamper-proof formulation for opioids is preferred.

  • Benefit: Tamper proof formulations of opioids have been linked to decreased diversion, abuse and death, when used for chronic pain. See the U.S Food and Drug Administration (FDA) site External Web Site Policy for more information. When used for acute pain, or in patients without opioid tolerance, long-acting opioids are associated with inadvertent opioid overdose death. Methadone pharmacology is complicated, and its routine use is associated with overdose death.
  • Harm: Tamper-proof formulations may not be covered or may have greater copay. For some situations, such as sleep, the duration of short-acting opioids is insufficient to treat pain.
  • Benefit-Harms Assessment: While there may be some select circumstances where use of long-acting opioids seems appealing in acute pain, they have failed to show benefit and are associated with overdose death. Using methadone in acute or chronic pain is associated with harm, owing to its unique pharmacology. If long-acting opioids are indicated, using a tamper-proof formulation may improve outcomes.
  • Relevant Resources: Hwang, Chang, & Alexander, 2015; Argoff, Kahan, & Sellers, 2014; Cassidy et al., 2014 ; Havens et al., 2014; Sessler et al., 2014; Butler et al., 2013; Coplan et al., 2013; Severtson et al., 2013; Manchikanti et al., 2012; Severtson et al., 2012; Dhalla et al., 2009

Patient-Provider Agreement (PPA)

Work Group Recommendation: Initiate a PPA at the time an opioid is prescribed for:

  • High-risk patients
  • Daily use of opioids >30 days
  • Patient transfers to a new clinic already on opioids
  • Episodic use up to 90 days over the course of a year
  • If none of the above, initiate a PPA after 90 days of opioids is prescribed
  • Benefit: PPAs provide the patient with a clear set of expectations in writing.
  • Harm: It has not been demonstrated that PPAs improve clinical outcomes. PPAs may be used as a pretext for dismissing undesirable patients.
  • Benefit-Harms Assessment: PPAs have not been proven an effective medical intervention; however, they provide a clear set of expectations for patients and clinicians. Executed and used correctly, a PPA can help prevent patient provider disagreement and allow the clinic to insist on consistent and universal practices for opioid-receiving patients. When done incorrectly, a PPA may cause patients to be dismissed from care without appropriate referrals or follow-up.
  • Relevant Resources: Dowell, Haegerich, & Chou, 2016; Hooten, Lamer, & Twyner, 2015; Noble et al., 2010; Starrels et al., 2010; Arnold, Han, & Seltzer, 2006

Consider Offering Naloxone

Work Group Recommendation: Clinicians should consider offering the patient and close contacts (family/friends/caretaker) a naloxone kit.

  • Benefit: Community access to naloxone may save lives that would otherwise be lost to opioid overdose death. Many states explicitly support and legally protect this use of naloxone in law.
  • Harm: Naloxone is not a treatment of the underlying causes of opioid overdose. Some forms of overdose are not reversed by a single dose of naloxone. Inducing opioid withdrawal may cause discomfort or other adverse effects. Training is required. Emergency services should be called when naloxone is used. Widespread use of naloxone may compromise its supply for those who need it the most.
  • Benefit-Harms Assessment: Home use of naloxone can save the life of a person who would otherwise die from an opioid overdose, but it does not correct the underlying cause of the overdose, and it requires training to use appropriately.
  • Relevant Resources: Coffin et al., 2016; Coffin & Sullivan, 2013; Centers for Disease Control and Prevention, 2012; Albert et al., 2011; Yokell et al., 2011; Strang et al., 2008

Acute or Acute on Chronic Pain

Work Group Recommendation: The first opioid prescription for acute pain should be no more than 20 low-dose, short-acting opioids or three days of medication, whichever is less. The total dose for acute pain should not exceed 100 morphine milligram equivalents (MME). For patients presenting in acute pain, already on chronic opioids, opioid tolerant or on methadone, use the same pill and dose limits as for opioid-naïve patients.

  • Benefit: This limited dosing would reduce surplus opioid prescriptions as well as reduce potential of opioid abuse, overdose and diversion. It encourages frequent follow-up for pain requiring opioids and facilitates early recognition of aberrant opioid use.
  • Harm: This limited dosing has potential to undertreat pain. It may cause inconvenience to patients by making them return to clinic for ongoing opioids and places some burden on providers arranging for early follow-up. In addition, some pain generators typically require more than three days of opioids.
  • Benefit-Harms Assessment: The medical community has typically overprescribed opioids for acute pain to ensure that no patient is ever undertreated, but at the risk of providing surplus opioids to the patient and the community, and specifically harming those with vulnerability to opioids. Lowering the total quantity of opioids prescribed will prevent much of this harm, but in exchange some patients with ongoing pain will receive insufficient opioids, forcing them to return for evaluation from their primary clinician. While this may be a short-term burden to the patient and system, it will, over time, lessen the burden to patients and clinicians by decreasing the harms of opioids. Those already taking opioids chronically have higher tolerance and thus may receive less analgesia from opioids. These patients are also at a higher risk, may have more comorbidity, may already be on opioid doses known to have adverse effects, and are likely to have an opioid patient-provider agreement. Thus, while treating the opioid-tolerant patient with equivalent doses will provide less analgesia, it will also mitigate harms.
  • Relevant Resources: Dowell, Haegerich, & Chou, 2016

Avoid Opioid Use for Chronic Pain

Work Group Recommendation: Avoid using opioids to treat patients with chronic pain.

  • Benefit: This will lower the total opioid use in the United States and the corresponding harms from opioids. Opioids have no proven efficacy for chronic pain but do have known harms. Preventing chronic exposure to opioids is easier and preferable to detoxing a patient chronically on opioids.
  • Harm: A subset of patients with chronic pain may benefit from chronic opioids. Patients already on chronic opioids cannot be easily detoxed from opioids, and this recommendation should not be taken as advice to detox existing chronic pain patients on long-term opioids.
  • Benefit-Harms Assessment: Pain that has no easily identifiable pain generator, and no cure, is a daunting problem in medicine and causes great suffering. These patients try many modalities of care and too often end up on chronic opioid therapy. There are no proven benefits of opioids for most patients with chronic pain, but there are proven harms. Until further knowledge emerges, it is prudent to avoid initiating opioids in these patients.
  • Relevant Resources: Chou et al., 2015; Chaparro et al., 2014; Manchikanti et al., 2006

Ongoing Treatment of Pain with Opioids

If the use of continued opioids is unavoidable, the Work Group members urge providers to consider the following issues.

Manage Dose Limits

Work Group Recommendation: Every effort should be made to keep chronic opioid using patients under 100 MME/day. Prescribers should consider seeking pain medicine consultation if greater than 100 MME is reached.

  • Benefit: Opioid doses greater than 100 MME/day are associated with overdose death; as the dose increases, so do the risk and the strength of the associations.
  • Harm: Some patients will have undertreated pain. Patients already on higher dose of opioids may struggle to lower their dose to a safe range. It is impossible to predict who will or will not overdose. Some patients who would not have been harmed by opioids will have their dose limited.
  • Benefit-Harms Assessment: Given a fairly clear dose response association between MME and death, patients should be kept under 100 MME/day, even at the cost of potentially undertreating pain in some.
  • Relevant Resources: Han et al., 2015; Turner & Liang, 2015; Franklin et al., 2012; Gomes et al., 2011; Dunn et al., 2010

Work Group Recommendation: Opioids should be avoided for patients with substance use disorder or concomitant benzodiazepines use. If a patient with substance use disorder is prescribed opioids, the opioid dose should be less than 50 MME/day. If patient requires both opioids and benzodiazepines, opioids should be less than 50 MME/day, taking into careful consideration the benzodiazepine dose. There should be good communication among providers regarding dosing.

  • Benefit: Patients with substance use disorder or benzodiazepine use are at higher risk of overdose if given opioids. Therefore, it is prudent to avoid opioids in these populations. If opioids are prescribed, the work group recommends a dose less than 50 MME/day to minimize adverse events.
  • Harm: Some patients will have undertreated pain.
  • Benefit-Harms Assessment: The risk of prescribing opioids to these populations outweighs the beneficial pain relief opioids may provide. Alternative pain management strategies should be employed.
  • Relevant Resources: Han et al., 2015; Turner & Liang, 2015

Opioid Rotation and Conversion

Work Group Recommendation: Opioid conversion tables should be used only as guidance when changing opioids. Doses of the new opioid should be reduced by 50% of the previous daily MME dose and titrated to achieve analgesia.

  • Benefit: This avoids overestimating opioid needs with a new opioid due to incomplete cross-tolerance and reduces the risk of adverse events and harm with the new opioid.
  • Harm: Patients may not experience adequate pain relief if taking opioids chronically and may experience mild withdrawal until the new opioid can be titrated to effective dose. This dose reduction may lead to more frequent dose changes and clinic visits until adequate pain control is achieved.
  • Benefit-Harms Assessment: Opioid conversion tables were developed from opioid-naïve patients and do not account for incomplete cross-tolerance in opioid-tolerant patients. Despite the chance of mild withdrawal, it is safer to underestimate the dose titrating as necessary than overestimate the dose causing harm.
  • Relevant Resources: Pasternak, 2014; Vissers et al., 2010; Fine & Portenoy, 2009; Pasternak, 2005

Opioid Hyperalgesia

Methadone

Work Group Recommendation: Initiating an opioid-tolerant patient on methadone for chronic pain should be reserved for experienced clinicians who are familiar with its use because its long half-life is associated with overdose and death.

  • Benefit: Trained clinicians are more familiar with the pharmacokinetic/pharmacodynamics properties of methadone and are better equipped to dose appropriately and provide the necessary monitoring to avoid adverse events.
  • Harm: Clinicians trained in methadone prescribing may not be available to all patients who may benefit from methadone.
  • Benefit-Harms Assessment: Methadone has a long and variable half-life that is not consistent between patients. It is highly lipophilic, and the respiratory depressant effect lasts longer than the analgesic effect. Methadone requires close follow-up and should only be initiated by clinicians experienced with its use.
  • Relevant Resources: Wong & Walker, 2013; Chou et al., “Clinical guidelines,” 2009

Fentanyl

Work Group Recommendation: Initiating transdermal fentanyl should be done only for patients with chronic opioid use greater than 60 MME daily, adequate subcutaneous adipose tissue and the cognitive ability to apply, remove and dispose of the patches safely. Patches should be removed after 72 hours, folded upon themselves sticky side inward and promptly flushed down the toilet. Sublingual fentanyl should be reserved for only those in need of palliative care for extreme pain and unable to take any alternatives.

  • Benefit: Fentanyl patches are long-acting, renal-safe synthetic opioids, and as such they occupy a fairly unique niche in the opioid pharmacopeia. There are not many replacement medications.
  • Harm: Fentanyl products are associated with accidental overdose deaths, including when an improperly disposed patch sticks to a toddler or household pet. Transdermal fentanyl is unsafe in cachectic patients lacking adipose tissue, given fentanyl’s lipophilicity. Sublingual (SL) fentanyl is exceedingly potent and apt to cause overdose if overused.
  • Benefit-Harms Assessment: Fentanyl is a highly potent, lipophilic synthetic opioid that can be used to good effect treating pain if opioids are indicated. However, due to its high potency, fentanyl has caused accidental overdoses, and the transdermal patches need special handling and disposal instructions. Only patients with established opioid tolerance should receive fentanyl. Fentanyl SL formulations can be very helpful but are best reserved for those in pain in the dying process.
  • Relevant Resources: U.S. Food and Drug Administration, 2013; U.S. Food and Drug Administration, 2012

Monitoring Considerations for Opioid Use

Prescription Monitoring Program (PMP)

Work Group Recommendation: The PMP should be queried in the following situations:

  • If opioids are prescribed in dental, emergency department and urgent care settings, and when doses are changed.
  • In every instance where there are concerns of substance use disorder, overdose, diversion, indeterminate pain disorder or polypharmacy.
  • For those patients with an established stable dose of opioids for a chronically painful condition and a history of compliance with the prescriber, PMP checks should be at least twice per year.

Consider querying the PMP when initiating opioid therapy.

  • Benefit: Detect clinician shopping, polypharmacy, opioid exposure and tolerance, and estimate the likely home supply of opioids. The PMP may reveal other prescribers whom to contact before prescribing opioids. A PMP query can help verify the patient’s story. A PMP query affects clinician decision-making and may lower overall opioids prescribed and overdoses.
  • Harm: PMP queries take time and training. Each state has a different program, with different laws governing their use, and incomplete cross-talk between states. Not every source of opioids is captured in a state PMP.
  • Benefit-Harms Assessment: To query the PMP is yet another time and energy burden on medical providers, but it provides invaluable knowledge about the patient’s exposure to opioids and other controlled substances, as well as other prescribers. Clinicians should know the loopholes and omissions inherent to their state’s PMP.
  • Relevant Resources: Han et al., 2015; Rutkow et al., 2015; Johnson et al., 2014; Albert et al., 2011

Urine Drug Screening

Work Group Recommendation: Routine random urine drug screens (UDS) for all patients on chronic opioid therapy for pain should be done at least once per year. UDS should be done if there is concern of aberrant behavior based on a prescriber’s assessments and clinical judgment.

  • Benefit: UDS can identify other substances being used that were not disclosed by the patient. UDS can identify when the patient is not taking the prescribed substance.
  • Harm: UDS are costly. UDS have many false positives and negatives and may be difficult to interpret. Patients may not be prepared to provide a UDS. Use of UDS has not been shown to improve outcomes. UDS does not, in itself, make a diagnosis of substance use disorder or diversion.
  • Benefit-Harms Assessment: Despite many complicating factors and lack of evidence that it improves outcomes, it is still standard of care, and universally recommended, that opioid prescribers check UDS on all patients routinely, and in any patient when there is concern of diversion or unsanctioned substance use. The ideal frequency and type of urine drug screen is not known.
  • Relevant Resources: Dowell, Haegerich, & Chou, 2016; Starrels et al., 2012; Reisfield, Goldberger, & Bertholf, 2009; Michna et al., 2007; Heit & Gourlay, 2004

Visit Frequency

Work Group Recommendation: When initiating an opioid prescription, patients should be monitored within a month to evaluate harms and benefits, and assess treatment goals. Patients on stable opioid doses should be seen every three months.

  • Benefit: Developing a strong relationship is important for both opioid prescribing and pain treatment. There is an increasing number of recommendations and regulations that apply to opioid prescribing. These can be time consuming and overwhelming to the patient if attempted on a single visit. Therefore, repeated education is necessary.
  • Harm: There is not certain evidence that frequency of visits improves outcomes. Increasing frequency of visits may be burdensome to patients. Some patients have maintained stability on opioids with less frequent visits and may expect to continue the current expectations.
  • Benefit-Harms Assessment: While there is a lack of definitive evidence, and this will consume health care resources and potentially burden patients, increasing the frequency of visits for those receiving opioids, in particular those early in treatment for their pain, allows for many critical tasks to take place between provider and patient including education, screening and relationship building.
  • Relevant Resources: Dowell, Haegerich, & Chou, 2016

Referrals for High-Risk Patients

Work Group Recommendation: Opioid prescribers should have a referral source for psychiatric treatment, substance use disorder treatment, physical therapy and pain medicine available if needed.

  • Benefit: It is important to provide patients with a multidisciplinary approach to the treatment of pain when necessary. Multidisciplinary care may improve pain outcomes and mitigate the harms caused by mental health and addiction, specifically lowering the risk of inadvertent overdose and death.
  • Harm: Access to addiction and psychiatric resource in the community may be sparse.
  • Benefit-Harms Assessment: Patients with mental health and/or addictive disorders receiving opioids are at high risk for harm, including death. To safely treat such patients, prescribers perform better and have better outcomes if they have access to referrals for assessment and treatment of these disorders.
  • Relevant Resources: Gaither et al., 2016; Reuben et al., 2015

If Opioid Use Disorder Is Suspected, Consider Referral to Addiction Medicine Specialist

Opioid Use Disorder Assessment

Work Group Recommendation: Opioid prescribers should recognize the symptoms of opioid use disorder. Opioid prescribers should understand the treatment options for opioid use disorder and have a referral source available.

  • Benefit: Patients with opioid use disorder (OUD) receiving opioids for pain are at high risk of aberrant behavior and overdose death. Making the diagnosis of OUD and offering the proper referral for treatment may be a lifesaving intervention. Buprenorphine and methadone, given by a certified and trained specialist in their use, confers mortality benefit for patients with OUD. Intramuscular naltrexone decreases illicit use of opioids.
  • Harm: Physicians are largely untrained at recognizing, counseling and treating patients with OUD. Referral options for medication-assisted therapy are sparse in many communities.
  • Benefit-Harms Assessment: Of all the patients receiving opioids for pain, those with OUD are at the greatest risk of harm. Yet knowledge of diagnosis and treatment of OUD is insufficient among opioid prescribers. It is critical that providers take the time to become versed with this important risk factor of harm from opioids.
  • Relevant Resources: Cousins et al., 2016; Gaither et al., 2016; Fullerton et al., 2014; Thomas et al., 2014; Carrieri et al., 2006

Offer Discontinuation of Opioids or Taper at Intervals of Six Months

Tapering Opioids

Work Group Recommendation: Once the patient and clinician agree to taper opioids, it should be individualized to the patient’s circumstances, and a referral source should be available. While tapering opioids, patients should be offered additional treatment options and frequent follow-up. Opioid tapering should be discussed and offered at intervals of six months for all patients on chronic opioids.

  • Benefit: Each patient has unique reactions to opioids and exposure to them, making uniform tapering protocols impractical. Patient involvement in their own taper may improve outcomes. Intensified care during an opioid taper may improve patient-doctor communication and identify complications early.
  • Harm: No good trial demonstrates how to best taper patients receiving opioids.
  • Benefit-Harms Assessment: Guidelines and protocols are encouraging less use of opioids and emphasizing the harms of opioids but no one can say with certainty how to best taper a patient already on opioids. A reasonable recommendation is that providers work closely with patients, monitoring for risks, and individualize an opioid taper.
  • Relevant Resources: Accurso & Rastegar, 2016; Dowell, Haegerich, & Chou, 2016; Berna, Kulich, & Rathmell, 2015